The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Novel genomic alterations driving tumor suppressor gene inactivation in multiple myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, shares insights from his research utilizing whole genome sequencing (WGS) in patients with newly diagnosed multiple myeloma to elucidate the temporal sequence of genomic events. His investigation concludes that there are genomic deletions prior to the known initiating events of hyperdiploidy (HRD) and translocations affecting the immunoglobulin heavy chain (IGH) locus, which underly the inactivation of tumor suppressor genes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
